Phaseline

Companies › Xencor

Xencor: clinical trials, targets and expected readouts

8 active drug programs in 9 registered trials: 8 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
vudalimab (XmAb20717)
Bispecific monoclonal antibody targeting CTLA-4 and TIGIT
CTLA4, TIGITPhase 2Ovarian Cancer–
XmAb819
Monoclonal bispecific antibody
–Phase 1Clear Cell Renal Cell CarcinomaFeb 2027
XmAb412
Monoclonal Bispecific Antibody
–Phase 1Not Applicable - Healthy Adult ParticipantsMay 2027
XmAb541
Monoclonal bispecific antibody
–Phase 1Ovarian CancerDec 2027
XmAb942
Antibody
–Phase 1Ulcerative Colitis (UC)Dec 2027
Plamotamab
CD40-engaging bispecific antibody
CD40Phase 1Rheumatoid ArthritisJun 2028
XmAb657–Phase 1HealthyOct 2028
XmAb808
Monoclonal bispecific antibody
–Phase 1Ovarian CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05032040vudalimab (XmAb20717)Phase 2Ovarian CancerOncologyOct 2025
NCT05433142XmAb819Phase 1Clear Cell Renal Cell CarcinomaOncologyFeb 2027
NCT07713485XmAb412Phase 1Not Applicable - Healthy Adult ParticipantsImmunologyMay 2027
NCT06276491XmAb541Phase 1Ovarian CancerOncologyDec 2027
NCT06619990XmAb942Phase 1Ulcerative Colitis (UC)ImmunologyDec 2027
NCT07230353PlamotamabPhase 1Rheumatoid ArthritisImmunologyJun 2028
NCT07284797XmAb657Phase 1HealthyImmunologyOct 2028
NCT07593092XmAb541Phase 1Ovarian CancerOncologyDec 2028
NCT07593092XmAb808Phase 1Ovarian CancerOncologyDec 2028

From the company's SEC filings

Cash of $60m on 2026-09-30; operating cash outflow about $162m a year; runway about 4 months at that burn, to Feb 2027

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CD40 (1) CTLA4 (1) TIGIT (1)

Companies with the same targets

AstraZeneca AbbVie Roche Summit Therapeutics Innovent Biopharmaceutical Technology (Hangzhou) Shanghai Henlius Biotech Genmab RANI Therapeutics Akamis Bio Alligator Bioscience

Companies built like this

MacroGenics Miltenyi Biomedicine TScan Therapeutics Agenus Huabo Biopharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.